Cyborg Cardiac Patch may Treat the Diseased Heart
More than 25% of the people on the national US waiting list for a heart will die before receiving one. Despite this discouraging figure, heart transplants are still on the rise. There just hasn't been an alternative. Until now. The "cyborg heart patch," a new engineering innovation from Tel Aviv University, may single-handedly change the field of cardiac research. The bionic heart patch combines organic and engineered parts. In fact, its capabilities surpass those of human tissue alone. The patch contracts and expands like human heart tissue but regulates itself like a machine.
The invention is the brainchild of Prof. Tal Dvir and PhD student Ron Feiner of TAU's Department of Biotechnology, Department of Materials Science and Engineering, and Center for Nanoscience and Nanotechnology. Their study was published today in the journal Nature Materials.
Science fiction becomes science fact
"With this heart patch, we have integrated electronics and living tissue," Dr. Dvir said. "It's very science fiction, but it's already here, and we expect it to move cardiac research forward in a big way.
"Until now, we could only engineer organic cardiac tissue, with mixed results. Now we have produced viable bionic tissue, which ensures that the heart tissue will function properly."
Prof. Dvir's Tissue Engineering and Regenerative Medicine Lab at TAU has been at the forefront of cardiac research for the last five years, harnessing sophisticated nanotechnological tools to develop functional substitutes for tissue permanently damaged by heart attacks and cardiac disease. The new cyborg cardiac patch not only replaces organic tissue but also ensures its sound functioning through remote monitoring.
"We first ensured that the cells would contract in the patch, which explains the need for organic material," said Dr. Dvir. "But, just as importantly, we needed to verify what was happening in the patch and regulate its function. We also wanted to be able to release drugs from the patch directly onto the heart to improve its integration with the host body."
For the new bionic patch, Dr. Dvir and his team engineered thick bionic tissue suitable for transplantation. The engineered tissue features electronics that sense tissue function and accordingly provide electrical stimulation. In addition, electroactive polymers are integrated with the electronics. Upon activation, these polymers are able to release medication, such as growth factors or small molecules on demand.
Cardiac therapy in real time
"Imagine that a patient is just sitting at home, not feeling well," Dr. Dvir said. "His physician will be able to log onto his computer and this patient's file - in real time. He can view data sent remotely from sensors embedded in the engineered tissue and assess exactly how his patient is doing. He can intervene to properly pace the heart and activate drugs to regenerate tissue from afar.
"The longer-term goal is for the cardiac patch to be able to regulate its own welfare. In other words, if it senses inflammation, it will release an anti-inflammatory drug. If it senses a lack of oxygen, it will release molecules that recruit blood-vessel-forming cells to the heart."
Dr. Dvir is currently examining how his proof of concept could apply to the brain and spinal cord to treat neurological conditions.
"This is a breakthrough, to be sure," Dr. Dvir said. "But I would not suggest binging on cheeseburgers or quitting sports just yet. The practical realization of the technology may take some time. Meanwhile, a healthy lifestyle is still the best way to keep your heart healthy."
Tel Aviv University (TAU) is inherently linked to the cultural, scientific and entrepreneurial mecca it represents. It is one of the world's most dynamic research centers and Israel's most distinguished learning environment. Its unique-in-Israel multidisciplinary environment is highly coveted by young researchers and scholars returning to Israel from post-docs and junior faculty positions in the US.
American Friends of Tel Aviv University (AFTAU) enthusiastically and industriously pursues the advancement of TAU in the US, raising money, awareness and influence through international alliances that are vital to the future of this already impressive institution.
Most Popular Now
RADAR-CNS (Remote assessment of disease and relapse - Central Nervous System), a major new research programme supported by the Innovative Medicines Initiative (IMI) start...Read more
UK healthcare technology company Patientrack has been recognised as providing one of the best eHealth solutions anywhere in Europe, in an EU competition focussed on healt...Read more
Merck, a leading science and technology company, announced today that the company has entered into an agreement with HAPPYneuron, a subsidiary of SBT Group of France, in ...Read more
Opinion Article by Steve Carvell, head of healthcare at CommonTime. Technology skills are in higher demand than ever. Look across any vertical and developers who can cre...Read more
A new centre for digital innovation which could transform the way mental health care is provided will be launched today. The Centre for Translational Informatics (CTI) is...Read more
8 - 9 September 2016, Flensburg, Germany. The first eHealth Innovation Days Conference at Flensburg University of Applied Sciences will offer a platform for networking, ...Read more
Royal Philips (NYSE: PHG; AEX: PHIA) has announced the Philips Sonicare FlexCare Platinum Connected, its latest innovation that uses Smart Sensor technology to help consu...Read more
24 June 2016, Martinsried, Germany. Biomax announces the 2016 Biomax Symposium on "Bringing Big and Complex Data into Clinical Practice" that will take place in Martinsr...Read more
Most Americans go online for information and support about health-related issues. But what exactly are they looking for? Researchers at the University of California, Rive...Read more